[1] Kim E H, Andriole G L, et al. Prostate cancer review[J]. Modern Medicine, 2018, 115(2): 131.
[2] Alcorn T,Ying H S.Leader of research on prostate cancer in china[J]. Lancet, 2015, 385(9965):321.
[3] 李星,曾晓勇.中国前列腺癌流行病学研究进展[J].肿瘤防治研究,2021,48(1): 98–102.
Li X, zen X Y. Advances in epidemiology of prostate cancer in China[J]. Cancer Research Prevention and Treatment, 2021, 48(1): 98–102.
[4] 何奇瑞,林思浩,王杰,等.局部进展期前列腺癌的诊治进展[J].中国男科学杂志,2020,34(6): 62–66.
He QR, Lin S H, Wang J, et al. Progress in the diagnosis and treatment of locally advanced prostate cancer[J]. Chinese Journal of Andrology, 2020, 34(6): 62–66.
[5] Yanai Y, Kosaka T, Hongo H, et al. Evaluation of prostate-specific antigen density in the diagnosis of prostate cancer combined with magnetic resonance imaging before biopsy in men aged 70 years and older with elevated psa[J]. Molecular And Clinical Oncology, 2018, 9(6): 656–660.
[6] Vilson F L, Li S, Brooks J D, et al. Sudden psa rise to >/=20 ng/ml and prostate cancer diagnosis in the united states: a population-based study[J]. Prostate, 2020, 12(6): 766–772.
[7] Chiu P K, Teoh J Y, Chan S Y, et al. Role of psa density in diagnosis of prostate cancer in obese men[J]. International Urology and Nephrology,2014,46(12): 2251–2254.
[8] Prensner J R, Iyer M K, Sahu A, et al. The long noncoding rna schlap1 promotes aggressive prostate cancer and antagonizes the swi/snf complex[J]. Nature Genetics, 2013, 45(11):1392–1398.
[9] Mehra R, Shi Y, Udager A M, et al. A novel RNA in situ hybridization assay for the long noncoding rna schlap1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer[J]. Neoplasia , 2014, 16(12): 1121–1127.
[10] Gallo-Oller G, Ordonez R, Dotor J, et al. A new background subtraction method for western blot densitometry band quantification through image analysis software[J]. Journal of Immunological Methods, 2018, 457: 1–5.
[11] Zhang W, Chen Z, Wang WW.Diagnostic value of roc curve evaluating serum related indexes for bloodstream infection in patients with hematopathy[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2020, 28(5): 1746–1749.
[12] Verbakel J Y, Steyerberg E W, Uno H, et al. Roc curves for clinical prediction models part 1. Roc plots showed no added value above the auc when evaluating the performance of clinical prediction models[J]. Journal Clinical Epidemiology, 2020, 126: 207–216.
[13] Silbert D, Matta N.Roc analysis to improve sensitivity and specificity of the plusoptix photoscreener[J]. Ophthalmic Research, 2012,7(1): 2.
[14] Mallett S, Halligan S, Collins G S, et al. Exploration of analysis methods for diagnostic imaging tests: Problems with roc auc and confidence scores in ct colonography[J]. PLoS One, 2014,9(10): e107633.
[15] Vale C L, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data[J]. Lancet,2020,396(10260): 1422–1431.
[16] Fu Z T, Guo X L, Zhang S W, et al. Statistical analysis of incidence and mortality of prostate cancer in china[J]. Zhonghua Zhong Liu Za Zhi,2020, 42(9): 718–722.
[17] Javaeed A, Ghauri S K, Ibrahim A, et al. Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review[J]. Oncology Reports, 2020,14(1): 449.
[18] VICTORIA J, SHARPM D,ELIZABETH B.TAKACS, M D : Central pain and complex motoric symptoms after gosarelin therapy of prostate cancer. Diagnosis and Treatment, 2010(4): 969–973.
[19] Leskinen MJ, Rantakokko-Jalava K, Manninen R, et al. Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (cpps) and localized prostate cancer[J]. Prostate,2003,55(2): 105–110.
[20] Testa U, Castelli G, Pelosi E.Cellular and molecular mechanisms underlying prostate cancer development: Therapeutic implications[J]. Medicines (Basel),2019,6(3): 82. |
